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Summary
Cyclin-dependent kinases (CDKs) restrict DNA repli-
cation origin firing to once per cell cycle by prevent-
ing the assembly of prereplicative complexes (pre-
RCs; licensing) outside of G1 phase. Paradoxically,
under certain circumstances, CDKs such as cyclin
E-cdk2 are also required to promote licensing. Here,
we show that CDK phosphorylation of the essential
licensing factor Cdc6 stabilizes it by preventing its
association with the anaphase promoting complex/
cyclosome (APC/C). APC/C-dependent Cdc6 proteoly-
sis prevents pre-RC assembly in quiescent cells and,
when cells reenter the cell cycle from quiescence,
CDK-dependent Cdc6 stabilization allows Cdc6 to ac-
cumulate before the licensing inhibitors geminin and
cyclin A which are also APC/C substrates. This novel
mechanism for regulating protein stability estab-
lishes a window of time prior to S phase when pre-
RCs can assemble which we propose represents a
critical function of cyclin E.
Introduction
DNA replication in eukaryotic cells initiates from large
numbers of replication origins distributed on multiple
chromosomes. A two-step mechanism regulates the
initiation of DNA replication, ensuring that the entire ge-
nome is precisely duplicated in each cell cycle (Bell and
Dutta, 2002; Blow and Dutta, 2005; Diffley, 2004). In the
first step, Cdc6 and Cdt1 collaborate with the origin
recognition complex (ORC) to load the putative replica-
tive helicase (Mcm2-7) into pre-RCs at replication ori-
gins. In the second step, two protein kinases, Cdc7 and
the S phase CDKs, convert pre-RCs into bidirectional
replisomes at each origin. DNA replication is limited to
once per cell cycle because these two steps are tem-
porally segregated: pre-RC assembly can only occur
from late mitosis through G1 phase, and once cells en-
ter S phase, pre-RCs can no longer assemble. Thus,
origins that have fired once cannot be relicensed until
they pass through the following mitosis.
In budding yeast, CDKs directly prevent pre-RC as-
sembly by inhibiting the function of all of the pre-RC
components thus limiting pre-RC assembly to G1
phase (Diffley, 2004). CDKs appear to play a similar role*Correspondence: john.diffley@cancer.org.uk
1Present address: Institute of Cancer Biology and Centre for Geno-
toxic Stress Research, Danish Cancer Society, Strandboulevarden
49, DK-2100 Copenhagen Ø, Denmark.in metazoans: inactivation of the mitotic CDK, cdc2,
causes endoreduplication (Itzhaki et al., 1997), and
treatment of postreplicative cells with a CDK inhibitor
induces relicensing (Ballabeni et al., 2004; Coverley et
al., 1996, 1998). However, metazoans also contain an
additional licensing inhibitor called geminin (Blow and
Dutta, 2005; McGarry and Kirschner, 1998). In human
cells, geminin is targeted for proteolysis by the APC/C
E3 ubiquitin ligase (McGarry and Kirschner, 1998), en-
suring that the licensing inhibitors geminin and cyclin
A are degraded from late mitosis through G1 phase,
allowing pre-RCs to assemble during this period.
In addition to targeting licensing inhibitors for prote-
olysis, the APC/C also targets the essential pre-RC as-
sembly factor, Cdc6, for proteolysis (Petersen et al.,
2000). Coregulation of licensing inhibitors and activa-
tors, however, would make it impossible for cells to
achieve a state where pre-RC components are all pre-
sent but licensing inhibitors are absent. Cyclin E can
either promote or inhibit pre-RC assembly, depending
on context (see Diffley [2004] for discussion). Here we
show that CDKs, including those containing cyclin E,
promote licensing by phosphorylating a regulatory do-
main of Cdc6, thus preventing its degradation by the
APC/C. This allows Cdc6 to accumulate before the li-
censing inhibitors geminin and cyclin A when quiescent
cells re-enter the cell cycle. We propose a simple model
to explain the positive role of cyclin E in licensing and
discuss how context might also allow cyclin E to be a
licensing inhibitor.
Results
CDKs Regulate Cdc6 Stability
We noticed that levels of endogenous Cdc6 protein in
human tissue culture cells were significantly reduced
very quickly after treatment with the CDK inhibitor, ros-
covitine. Other APC/C substrates including geminin,
cyclin A, and cyclin B were unaffected by roscovitine
during the same time interval. At the concentrations
used, roscovitine should primarily inhibit CDKs (Meijer
et al., 1997). Figure 1B shows that the levels of endoge-
nous Cdc6 were also dramatically reduced after cdk2
levels were reduced using siRNA. The effects of roscov-
itine on Cdc6 are seen after just 2 hr (Figure 1A), before
any significant alteration in cell cycle distribution can
occur, and depletion of cdk2 by siRNA did not affect
the distribution of cells in the cell cycle (see Figure S1A
in the Supplemental Data available with this article on-
line). To determine whether the reduction in Cdc6 levels
is due to changes in protein stability, we examined the
rate of Cdc6 disappearance after addition of cyclohexi-
mide (CHX) to prevent new Cdc6 synthesis. Endoge-
nous Cdc6 was relatively unstable, with a half-life of
approximately 1 hr based on initial rates of disappear-
ance, and became even more unstable after roscovitine
treatment, with a half-life significantly less than 1 hr
(Figure 1C). A similar decrease in half-life was seen af-
ter depletion of either cyclins E1 and E2 or cdk2 (Figure
Cell
916Figure 1. Cdc6 Stability Is Regulated by
CDK Activity
(A) Loss of Cdc6 expression in response to
CDK inhibition. Exponentially growing U2OS
cells were treated with Roscovitine and total
lysates were immunoblotted for the indi-
cated proteins. cdk7 was included as a load-
ing control.
(B) Cdc6 protein levels decline in response
to cdk2 depletion. U2OS cells were left un-
treated or transfected with cdk2 siRNA for
72 hr, and total cell lysates were probed for
Cdc6 and cdk2. Mcm7 was included as a
loading control.
(C) The degradation of Cdc6 is accelerated
by CDK inhibition. Cycloheximide was added
with or without Roscovitine to U2OS cells for
the indicated times, and the abundance of
Cdc6 was monitored by immunoblotting.
(D and E) Stabilization of Cdc6 by elevated
cyclin E levels.
(D) U2OS cells were transfected with indi-
cated combinations of HA-Cdc6 and myc-
cyclin E for 24 hr and incubated for an addi-
tional 3 hr in the presence or absence of
Roscovitine. Expression of the transfected
proteins was analyzed by immunoblotting.
(E) U2OS cells transfected as in (D) were
treated with CHX for the indicated times and
the stability of HA-Cdc6 was assayed by im-
munoblotting.
(F) Endogenous Cdc6 but not other APC/C
substrates accumulates in response to cyclin
E overexpression. Cells were transfected with
the indicated constructs and CD20 expression
plasmid. Productively transfected cells were
then isolated with magnetic beads coated with
CD20 antibody and processed for immuno-
blotting.S1B). These experiments indicate that CDK inhibition
reduces Cdc6 protein levels at least in part by destabi-
lizing the Cdc6 protein.
Overexpression of cyclin E (Figure 1D) or cyclin A
(Figure S3A) caused an increase in levels of cotrans-
fected Cdc6 tagged with the HA epitope (HA-Cdc6).
This accumulation of Cdc6 was blocked by roscovitine,
suggesting that CDK catalytic activity is required for
Cdc6 accumulation (Figure 1D). Cyclin E overexpres-
sion dramatically stabilized HA-Cdc6, increasing its
half-life to far greater than 3 hr (Figure 1E). Because
transfected Cdc6 can be regulated differently from the
endogenous Cdc6 (Alexandrow and Hamlin, 2004), we
cotransfected cells with a cell-surface marker (CD20)
which allowed us to specifically purify transfected cells.
In these purified cells, endogenous Cdc6 levels were
significantly increased after cotransfection with myc-
cyclin E (Figure 1F). This effect was enhanced by cot-
ransfection of myc-cyclin E with HA-cdk2. Figure S1A
shows that overproduction of cyclin E had little or no
effect on cell cycle distribution. As with the roscovitine
treatment, myc-cyclin E with or without HA-cdk2 had
no effect on levels of other APC/C substrates such as
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ayclin A or cyclin B (Figure 1F). Taken together, these
xperiments indicate that the stability of both endoge-
ous and transfected Cdc6 is regulated by cyclin E-cdk2.
tabilization Is Mediated by CDK Sites
n the Cdc6 NTD
tabilization could be due to direct phosphorylation of
dc6 or to some indirect effect of CDKs. Eukaryotic
dc6 proteins contain a regulatory N-terminal domain
NTD) that is not directly involved in pre-RC assembly
Drury et al., 1997). Cdc6 is a good substrate for cyclin
-, A-, and B-associated CDKs (Herbig et al., 2000), and
ndicated in boxes in Figure 2A are three serine resi-
ues known to be phosphorylated by CDKs in human
ells (Jiang et al., 1999; Petersen et al., 1999). Two of
hese lie in close proximity to conserved APC/C de-
truction boxes (gray; Petersen et al., 2000). The first
serine 54) is next to an RXXL-type destruction box
hile the second (serine 74) is near a KEN-type de-
truction box. The RXXL motif is found in all of the ver-
ebrate Cdc6 sequences, while the KEN box is present
n all of the vertebrate Cdc6 sequences except XlCdc6a,
n isoform of Cdc6 specific for early Xenopus embryos
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917Figure 2. Cdc6 Is Stabilized by Phosphorylation of In Vivo CDK Sites
(A) Conserved regulatory motifs in Cdc6 from higher eukaryotes.
(B) Sensitivity of Cdc6 to modulation of CDK activity is mediated by the N terminus. U2OS cells were transfected with full-length or
N-terminally truncated HA-Cdc6 (NT) in the presence or absence of myc-cyclin E and lysates were probed for the indicated proteins.
(C) Expression level of Cdc6 CDK phosphorylation site mutants. U2OS cells were transfected with the indicated HA-Cdc6 constructs and
processed for immunoblotting.
(D) Stabilization of Cdc6 by CDK phospho-mimicking mutations. U2OS cells transfected with HA-Cdc6 wt or DDD were treated with CHX for
the indicated times and analyzed for total Cdc6 levels by immunoblotting.
(E and F) Phospho-mimicking mutations in Cdc6 render it insensitive to CDK deregulation.
(E) U2OS cells treated as in (C) were incubated with or without Roscovitine for the final 3 hr of transfection and analyzed for Cdc6 levels
by immunoblotting.
(F) U2OS cells were transfected with combinations of HA-Cdc6 constructs, myc-cyclin E, and GFP as indicated and processed for immu-
noblotting.(Tikhmyanova and Coleman, 2003). Xenopus embryos
also lack Cdh1 (Littlepage and Ruderman, 2002), which
is involved in recognizing the KEN box (Pfleger et al.,
2001). There are several other potential CDK sites (bold)
and an RXL or Cy motif (underlined) which acts as a
docking site for cyclins (Figure 2A).
We examined the effects of modulating CDK activity
on mutant Cdc6 proteins. Overexpression of myc-
cyclin E increased the levels of both HA-Cdc6 and
endogenous Cdc6 but did not affect the levels of HA-
Cdc6NT (Figure 2B), a version of Cdc6 lacking the en-
tire NTD, indicating that the NTD is required for CDKs
to modulate Cdc6 stability. We constructed mutant ver-
sions of Cdc6 in which the three known CDK-phosphor-
ylated serines were replaced with either alanine (AAA)
to mimic the unphosphorylated state or aspartic acid
(DDD) to mimic the phosphorylated state. Expressionof these mutant proteins had no effect on the distribu-
tion of cells in the cell cycle (Figure S2). The DDD mu-
tant was expressed at levels higher than the wild-type
protein, while the AAA mutant was expressed at levels
lower than the wild-type protein (Figure 2C). The DDD
mutant was significantly more stable than the wild-type
protein after CHX addition (Figure 2D). Moreover, the
levels of both wild-type HA-Cdc6 and endogenous
Cdc6 but not the DDD mutant were sensitive to roscovi-
tine treatment (Figure 2E). The unphosphorylatable AAA
mutant was destabilized even further, probably be-
cause roscovitine activates the APC/C (Listovsky et al.,
2000). Finally, Figure 2F shows that, in contrast to wild-
type Cdc6, both the AAA and DDD mutants were unaf-
fected by cyclin E overexpression together, indicating
that cyclin E regulates the stability of Cdc6 by direct
phosphorylation.
Cell
918CDK phosphorylation sites of the NTD have been
previously implicated in causing relocalization of trans-
fected (but not endogenous) Cdc6 protein to the cyto-
plasm (Alexandrow and Hamlin, 2004; Jiang et al., 1999;
Petersen et al., 1999). Although our experiments clearly
show that the stability of the endogenous as well as
transfected Cdc6 is regulated by CDKs, we wanted to
address the possibility that altered subcellular localiza-
tion might contribute to stabilization of the transfected
proteins. Addition of a cassette containing three consti-
tutive nuclear localization sequences (3X-NLS) to the
DDD mutant caused it to reside almost entirely in the
nucleus. Under these conditions, the Cdc6 DDD protein
was still extremely stable (Figure S3). Thus, the effects
of CDKs on Cdc6 stability are independent from the
effects of CDKs on subcellular localization.
CDK Phosphorylation Blocks APC/C-Dependent
Proteolysis In Vivo and In Vitro
Cdc6 has previously been shown to be a substrate for
the APC/C (Petersen et al., 2000). Transfected wild-type
and AAA HA-Cdc6 as well as endogenous Cdc6 accu-
mulated to higher levels after treatment with MG132
(Figure 3A), while the DDD mutant was unaffected by
MG132 treatment, indicating that the differences in the
stability of the Cdc6 mutants are mediated by the pro-
teasome. Overexpression of the APC/C activator Cdh1
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(A) The differential stability of phosphorylation site mutants of Cdc6 is proteasome-dependent. Exponentially growing U2OS cells were
transfected with HA-Cdc6 constructs in the presence or absence of MG132, harvested at the indicated times after transfection, and the
accumulation of ectopic Cdc6 was analyzed by immunoblotting.
(B and C) Phospho-mimicking mutations in Cdc6 protect it from APC/CCdh1-mediated proteolysis.
(B) U2OS cells were transfected with HA-Cdc6 constructs and myc-Cdh1, and total cell extracts were probed for the ectopic proteins.
(C) U2OS T-REx cells were transfected with HA-Cdc6 and myc-Cdh1/Tet-On, incubated for 24 hr to allow the accumulation of HA-Cdc6, after
which Doxycycline was added to induce myc-Cdh1 expression for the indicated times. Cells were processed as in (B).
(D) The stability difference between Cdc6 wt and DDD depends on Cdh1. U2OS cells were transfected with control or Cdh1 siRNAs for 24 hr,
transfected with HA-Cdc6 wt or DDD for an additional 24 hr, and the half-lives of the transfected proteins were assessed by CHX treatment
for the indicated times and immunoblotting.s sufficient to activate the APC/C irrespective of cell
ycle position and destabilizes wild-type Cdc6 (Pet-
rsen et al., 2000; Sorensen et al., 2000; Figure 3B).
dh1 overexpression also reduced AAA HA-Cdc6 levels
ut had no effect on the DDD mutant (Figure 3B). To
xamine this in more detail, the HA-Cdc6 constructs
ere cotransfected with tetracycline-inducible myc-
dh1 constructs. Transfections were adjusted so the
nitial levels of mutant proteins were similar. After accu-
ulation of the HA-Cdc6 proteins, doxycycline was
dded to induce myc-Cdh1. This induced rapid degra-
ation of wild-type and the AAA mutant but not the
DD mutant, which remained at high levels after Cdh1
nduction (Figure 3C). Even when targeted to the nu-
leus with the 3XNLS cassette, the DDD mutant was
esistant to Cdh1-dependent degradation (Figure S3H).
onversely, reduction of Cdh1 by siRNA significantly
tabilized wild-type HA-Cdc6 but had no effect on the
lready stabilized DDD mutant (Figure 3D). Figure 4A
hows that polyubiquitylated forms of the wild-type but
ot DDD Cdc6 were detected following expression of
dh1 and His-tagged ubiquitin, indicating that, in con-
rast to the wild-type protein, the DDD mutant is not
olyubiquitylated in vivo. Thus, the wild-type and AAA
utant are APC/C targets, but the DDD mutant is resis-
ant to APC/C -mediated degradation.
We next examined the degradation of an N-terminal
CDKs Regulate APC/C-Dependent Cdc6 Proteolysis
919Figure 4. CDK Phosphorylation of Cdc6 Interferes with Its Recognition by APC/CCdh1
(A) Selective ubiquitination of wt Cdc6 in response to reactivated APC/CCdh1. U2OS T-REx cells were cotransfected with Cdh1 (Tet-On) and
indicated combinations of Cdc6 and His-tagged Ubiquitin. Twenty-four hr after transfection, Cdh1 was induced by addition of Doxycycline,
and cells were incubated in the presence of MG132 for 6 hr before denaturing lysis. Ectopic Cdc6 in total extracts and fractions purified on
Ni2+-NTA was detected by HA immunoblotting.
(B) Degradation of Cdc6 fragments in quiescent cell extracts. The degradation of 35S-labeled N-terminal fragments of Cdc6 was analyzed
over time by SDS-PAGE and autoradiography. A DB mutant (R56A, L59A, K81A, E82A, and N83A) containing inactivated D- and KEN-boxes
was used as a control.
(C) CDK-phosphorylated Cdc6 is insensitive to ubiquitylation by purified APC/C in vitro. Ubiquitination reactions were performed using
immunopurified APC/C, E1 and E2 enzymes, and Cdh1. Unphosphorylated or Ser54/74-phosphorylated Biotin-conjugated Cdc6 peptides
(125 M) were used as substrates and detected by immunoblotting with anti-Biotin antibodies.
(D) CDK phosphorylation of Cdc6 regulates its affinity for Cdh1. U2OS cells were transfected with different amounts of HA-Cdc6 plasmids to
balance their expression, and total cell extracts were subjected to immunoprecipitation with anti-HA antibodies. Cdh1 and HA-Cdc6 were
detected by immunoblotting.Cdc6 fragment in concentrated extracts from quiescent
cells (Rape and Kirschner, 2004). Wild-type Cdc6 was
rapidly degraded in these extracts whereas the DDD
mutant as well as a construct in which the Cdc6 de-
struction box was mutated (DB) were considerably
stabilized (Figure 4B), indicating that the DDD mutant
is resistant to APC/C-dependent proteolysis in vitro.
We used affinity-purified APC/C from quiescent cells
in a cell-free system (Kramer et al., 2000) to examine
polyubiquitylation of biotinylated peptides spanning
the destruction boxes in Cdc6. Polyubiquitylated forms
of the Cdc6 peptide could be readily detected when
incubated in the presence of the complete system, and
this was greatly reduced when the E2 enzyme (UbcH10)
was omitted from the reaction (Figure 4C). However,
when the Cdc6 peptide was phosphorylated on Ser54
and Ser74, it was not polyubiquitylated in parallel reac-
tions. Together, these results indicate that phosphoryla-
tion of the Cdc6 NTD by CDKs prevents its proteolysisby preventing APC/C-dependent polyubiquitylation. Fi-
nally, Cdh1 could be detected in HA immunoprecipi-
tates with either wild-type or AAA HA-Cdc6 but not
DDD HA-Cdc6 (Figure 4D). Cdh1 coimmunoprecipi-
tated with wild-type but not AAA HA-Cdc6 always ap-
pears as a doublet. The reason for this is currently un-
known. We propose the inability of DDD Cdc6 to interact
with APC/C accounts for its resistance to APC/C-medi-
ated proteolysis.
CDK-Dependent Stabilization Allows
Early Cdc6 Accumulation
As shown above, APC/C-dependent proteolysis of
Cdc6 is modulated by CDK phosphorylation of the
Cdc6 NTD. In trying to understand why this elaborate
regulatory mechanism exists, we were struck by the
finding that cyclin E plays a positive, essential role in
licensing specifically when quiescent cells reenter the
cell cycle (Geng et al., 2003) and that cyclin E cooper-
Cell
920ates with Cdc6 to stimulate licensing in vitro (Coverley
et al., 2002). We considered that phosphorylation of the
Cdc6 NTD by cyclin E-cdk2 might promote Cdc6 stabi-
lization prior to the inactivation of the APC/C by cyclin
A (Sorensen et al., 2000). This would ensure that, in
cells reentering the cell cycle, Cdc6 would accumulate
before the licensing inhibitors geminin and cyclin A.
To assess the feasibility of this idea, we examined
the reaccumulation of endogenous proteins after se-
rum-starved cells were stimulated to reenter the cell cy-
cle. Cdc6 as well as Cdt1, geminin, Cdc20, and cyclin
A were absent after serum starvation (t = 0, Figure 5A).
Endogenous Cdc6 and Cdt1 both appeared approx-
imately 10 hr after serum addition, coincident with
the loading of Mcm6 onto chromatin. This was 3–4 hr
earlier than the appearance of other APC/C substrates,
geminin, cyclin A, and Cdc20, consistent with the hy-
pothesis.
Two predictions of this model are that Cdc6 appear-
ance should coincide with appearance of cyclin E ki-
nase activity and that Cdc6 should be quantitatively
phosphorylated in the NTD. To test the first prediction,
cyclin E and cyclin A immunoprecipitates made from
extracts of cells released from quiescence for various
times were assayed for histone H1 kinase activity. Al-
though cyclin E protein was present in the serum-
starved cells, there was little or no associated H1 ki-
nase activity (Figure 5B), perhaps due to the presence
of CDK inhibitors. Cyclin E-associated histone H1 ki-
nase activity first appeared approximately 10 hr after
serum stimulation, coinciding with the appearance of
Cdc6 protein and preceding the appearance of cyclin
A-associated kinase activity by 4 hr.
Using a phospho-specific antibody, Figure 5B shows
that as soon as Cdc6 appears, phospho-ser54 could
be detected. Treatment of extracts with λ phosphatase
completely eliminated recognition of endogenous and
HA-Cdc6 by the phospho-specific antibody (but not
anti-Cdc6 antibody) in both immunoblots and immuno-
precipitations (Figure 5C). Figure 5D shows that this
phospho-specific antibody can quantitatively deplete
Cdc6 from extracts from either exponentially growing
cells or serum-starved cells which had been serum
stimulated for 10 hr (when Cdc6 first appears). Thus,
upon reentry into the cell cycle, Cdc6 accumulates with
cyclin E-associated kinase activity and is quantitatively
phosphorylated on at least one of the residues impli-
cated in its stabilization.
Figure 5E shows that constitutively expressed wild-
type HA-Cdc6 accumulates approximately 10 hr after
serum stimulation, coincident with the endogenous
Cdc6 but before cyclin A (Figure 5E). Accumulation of
the AAA mutant was delayed 2–4 hr relative to the en-
dogenous protein and paralleled the appearance of
cyclin A, while the DDD mutant accumulated several
hours earlier than the endogenous protein. These ex-
periments, taken with previous results, support the idea
that Cdc6 is stabilized by cyclin E-cdk2 phosphoryla-
tion before other APC/C targets can accumulate upon
cell cycle reentry.
Cdc6 Stabilization Promotes Pre-RC Assembly
To determine whether this mechanism can contribute
to the ability of Cdc6 to support licensing, we needed
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do develop licensing assays that would allow us to ex-
mine the functionality of Cdc6 mutants in the absence
f endogenous Cdc6. We utilized the fact that quies-
ent T98G cells lack both Cdc6 and Cdt1. Figure 6A
hows that wild-type and AAA mutant HA-Cdc6 were
nable to accumulate in quiescent cells, while the DDD
utant (as well as the Cdc6 destruction box mutant,
DB—Figure 6B) accumulated to high levels, consis-
ent with the idea that the DDD mutant is resistant to
PC/C-dependent proteolysis. Wild-type Cdt1 can
eadily accumulate in quiescent cells (Figure 6C), and
verproduction of Cdh1 does not affect Cdt1 levels
Figure S4), indicating that Cdt1 is not an APC/C sub-
trate. The DDD mutant but not wild-type HA-Cdc6 pro-
oted the loading of Mcm6 onto chromatin in quies-
ent cells when coexpressed with Cdt1 (Figure 6C).
oexpression of Cdt1 was required for this loading in
0 cells (Figure 6D). Our results contrast slightly with
reviously published work showing that expression of
ild-type Cdc6 from an adenovirus expression vector
romoted Cdc6 accumulation and Mcm2-7 loading in
uiescent cells (Cook et al., 2002). The difference be-
ween our results is likely due to higher expression
evels from the adenovirus vector. To extend our find-
ngs, we serum-stimulated quiescent cells in the pres-
nce of roscovitine, which prevents the accumulation
f endogenous Cdc6 and Cdt1, presumably in part by
nterfering with E2F activation (Figure 6E). Ectopic ex-
ression of Cdt1 was sufficient to promote its accumu-
ation; however, neither wild-type nor the AAA mutant
A-Cdc6 could accumulate under these conditions
Figure 6E). Figure 6F shows that these Cdc6 con-
tructs were also unable to act with Cdt1 to support
cm2-7 loading significantly above background levels.
y contrast, the DDD mutant accumulated efficiently
pon serum addition in the presence of roscovitine
Figure 6E) and could support significant Mcm2-7 load-
ng (Figure 6F). Therefore, only the DDD mutant can effi-
iently accumulate and support licensing in the pres-
nce of active APC/C.
To examine the role of cyclin E in promoting Cdc6
tabilization and licensing during G1 phase, we used
iRNA to deplete cyclins E1 and E2. Figure S5 shows
hat endogenous Cdc6 levels drop significantly a few
ours after release from a nocodazole arrest consistent
ith previous work (Mendez and Stillman, 2000), pre-
umably reflecting APC/C-dependent proteolysis. De-
letion of cyclins E1 and E2 from nocodazole-arrested
ells prevented the reaccumulation of Cdc6 during the
ubsequent G1 phase after release from the nocoda-
ole arrest (Figure S5). This delay could have been a
irect effect on Cdc6 stability or an indirect effect on
dc6 transcription during G1 phase. So, we examined
he effect of cyclin E depletion on accumulation of tet-
acycline-inducible Cdc6. Cyclins E1 and E2 were de-
leted in nocodazole-arrested cells and doxycycline
as added upon release from the nocodazole arrest.
igure 6G shows that the accumulation of wild-type
A-Cdc6 was significantly delayed in the absence of
yclin E. By contrast, the accumulation of the DDD mu-
ant was unaffected by cyclin E knockdown (Figure 6H).
To examine the importance of cyclin E-dependent
tabilization of Cdc6 on licensing, we used siRNA to
eplete endogenous Cdc6 in nocodazole-arrested cells.
CDKs Regulate APC/C-Dependent Cdc6 Proteolysis
921Figure 5. Kinetics of Cdc6 Accumulation after Serum Stimulation
(A) Cdc6 accumulates earlier than other APC/C targets following cell cycle reentry. T98G cells rendered quiescent by serum starvation were
released into the cell cycle by serum stimulation, harvested at various times, and total cell extracts were immunoblotted for APC/C and
non-APC/C substrates. In parallel, cells at each time point were subjected to chromatin fractionation to monitor pre-RC assembly in G1
(lower panels).
(B) CDK phosphorylation of Cdc6 in G1 correlates with cyclin E- but not cyclin A-associated kinase activity. Total extracts from cells treated
as in (A) were processed for immunoblotting or subjected to kinase activity measurements for cyclin E and A as indicated.
(C) Characterization of a phospho-Ser54 antibody to Cdc6. Lysates from exponentially growing T98G cells were left untreated or incubated
with λ phosphatase. Lysates were then subjected to immunoblotting or immunoprecipitation with Cdc6 pS54 antibody.
(D) The total pool of Cdc6 is phosphorylated on Ser54. Total cell extracts were prepared from cells kept quiescent, released for 10 hr from
quiescence, or growing exponentially. Lysates were then subjected to three rounds of depletion with Cdc6 pS54 antibody or rabbit preimmune
serum (mock) and immunoblotted for the indicated proteins.
(E) Accumulation of Cdc6 alleles after cell cycle reentry. Cells treated as in (A) were transfected with HA-Cdc6 constructs upon release into
the cell cycle, harvested at various times after serum stimulation, and immunoblotted for the indicated proteins in total cell extracts.
Cell
922Figure 6. Phospho-Mimicking Cdc6 Drives pre-RC Assembly in the Absence of CDK Activity
(A) Phospho-mimicking mutations allow efficient expression of Cdc6 in G0. T98G-T cells were transfected with Tet-On constructs for HA-
Cdc6, serum-starved for 48 hr, and ectopic Cdc6 expression was induced for the indicated times by addition of Doxycycline. Expression of
ectopic Cdc6 was analyzed by immunoblotting.
(B) Expression of Cdc6 in G0 by phospho-mimicking or destruction box mutations. Quiescent T98G cells transfected with indicated constructs
were assayed for the expression of ectopic proteins by anti-HA immunoblotting.
(C and D) Cdc6 DDD drives pre-RC assembly in G0 in the presence of Cdt1. T98G cells were serum-starved for 72 hr and cotransfected with
indicated Cdc6 constructs and CD20 expression plasmid in the presence (C) or absence (D) of Cdt1 for an additional 24 hr. Positively
transfected cells were then isolated with CD20-coated beads and processed for chromatin fractionation and immunoblotting.
(E and F) Cdc6 DDD selectively stimulates pre-RC assembly in CDK-inhibited G1 cells. Quiescent T98G cells were transfected with the
indicated constructs and H2B-GFP 4 hr before serum stimulation. Two hours after G0 release, Roscovitine was added where indicated, and
cells were incubated for an additional 14 hr, harvested, and processed for immunoblotting (E) or immunofluorescent detection of chromatin
bound Mcm6 in transfected cells, as a measure of pre-RC assembly (F). Results show the mean of two independent experiments. Approxi-
mately 200 transfected cells were counted in each sample. Error bars in (F) represent the standard error of the mean.
(G and H) The accumulation of Cdc6 in G1 depends on its phosphorylation mediated by cyclin E. U2OS lines inducibly expressing Cdc6 wt
(G) or DDD (H) were transfected with control or cyclin E1/E2 siRNA for 24 hr and arrested in mitosis with Nocodazole for an additional 12 hr.
Cells were then released from the block in the presence of Doxycycline to induce the ectopic proteins, and their accumulation at various
times after the release was monitored by immunoblotting.
(I and J) Depletion of Cdc6 prevents pre-RC assembly upon exit from mitosis. Asynchronous U2OS cells were transfected with control (open
bars) or Cdc6 (closed bars) siRNA for 24 hr, after which Nocodazole was added for an additional 12 hr. Pre-RC formation in Nocodazole-
arrested cells or cells released from the block for 3 hr was then assessed as in (E) and (F).
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(K and L) Phospho-mimicking but not wt Cdc6 overrides the requirement of cyclin E for pre-RC assembly in G1 cells depleted for endogenous
Cdc6. U2OS/HA-Cdc6 wt (K) or DDD (L) cell lines were transfected with Cdc6 siRNA alone (gray bars) or a combination of Cdc6 and cyclin
E1/E2 siRNAs (black bars) for 24 hr, treated with Nocodazole for an additional 12 hr, and mitotic cells were then released from the block for
3 hr, after which the cells were kept repressed (open bars) or induced to express Cdc6 by the addition of Doxycycline (closed bars) for the
indicated times. Pre-RC assembly was scored as in (F).
sponse to DNA damage, for example, by means of p53-Figures 6I and 6J show that this prevented loading of
Mcm6 onto chromatin after release from the nocoda-
zole arrest. We next examined the effects of cyclin E
depletion on the capacity of tetracycline-inducible,
siRNA-resistant Cdc6 constructs to promote licensing.
Figure 6K shows that Mcm6 loading by wild-type Cdc6
was significantly delayed after depletion of cyclin E
(compare solid gray and black bars). Again, by con-
trast, the DDD mutant showed no delay in licensing
after cyclin E depletion (Figure 6L). Therefore, cyclin E
contributes to licensing during G1 phase by stabilizing
the Cdc6 protein.
Discussion
We propose a model to resolve the paradoxical situa-
tion whereby Cdc6, an essential pre-RC component, as
well as geminin and cyclin A, pre-RC inhibitors, are all
targeted for degradation by the APC/C (Figure 7). Dur-
ing quiescence, the highly active APC/C ensures that
Cdc6 as well as geminin and cyclin A are absent from
cells. The absence of Cdc6 contributes to preventing
inappropriate pre-RC assembly in quiescence. When
cells are stimulated to reenter the cell cycle, E2F-de-
pendent transcription is activated, in part, by cyclin
E-cdk2. Neither geminin nor cyclin A can accumulate
initially because the APC/C is active; however, cyclin E,
which is an E2F target but not an APC/C substrate, can
accumulate during this period. Cyclin E-cdk2 phospho-
rylates the Cdc6 NTD, specifically preventing Cdc6
degradation via the APC/C, allowing Cdc6 to accumu-
late before geminin and cyclin A. Because Cdt1 is an
E2F target but not an APC/C substrate, it can accumu-
late together with Cdc6. Later in G1 phase, the APC/C
becomes inactivated, allowing the licensing inhibitors
geminin and cyclin A to accumulate. Thus, Cdc6 stabili-
zation ensures that all of the essential pre-RC compo-
nents are present for a window of time in late G1 phase
to allow licensing. Then, as cells enter S phase, this
window is closed by the accumulation of licensing in-
hibitors.Figure 7. Model of the Regulation of pre-RC Assembly after Cell
Cycle Reentry
Details of the model are described in the text.trolling protein degradation: CDK phosphorylation-
dependent masking of destruction boxes in Cdc6 di-
rectly prevents APC/C-dependent proteolysis. CDKs
control the stability of other key cell cycle regulators
such as CDK kinase inhibitors by phosphorylating them
and targeting them to the SCF E3 ubiquitin ligase (Ang
and Harper, 2005). Thus, CDKs can both stabilize and
destabilize proteins.
The model in Figure 7 applies to the regulation of
licensing when cells reenter the cell cycle from quies-
cence. Proliferating cells must also establish a window
of time (at the end of mitosis) when all of the required
pre-RC components are present and active and the li-
censing inhibitors are absent. Our experiments indicate
that CDK-dependent Cdc6 phosphorylation prevents
APC/C-dependent degradation even in proliferating
cells. However, it is clear from genetic analysis in mice
that cyclin E is not required in normally proliferating mi-
totic cells (Geng et al., 2003). Moreover, we have found
that depletion of cyclin E in nocodazole-arrested cells
inhibits licensing if Cdc6 expression is limited to G1
phase (Figures 6G–6L) but does not inhibit licensing at
the end of mitosis (data not shown). We suggest three
possible, nonexclusive mechanisms to explain the lack
of a cyclin E requirement for licensing on telophase
chromosomes. Firstly, Cdc6 made in the previous cell
cycle may be resistant to APC/C-dependent proteoly-
sis, perhaps because it is already bound to chromatin
before mitosis. This would allow Cdc6 to persist at ori-
gins after geminin and cyclin A have been degraded.
Secondly, instead of cyclin E-cdk2, another CDK com-
plex, perhaps involving one or more of the mitotic
cyclins, may phosphorylate and stabilize Cdc6 during
mitosis. Finally, Cdc6 may be specifically targeted for
proteolysis by APC/CCdh1, whereas geminin and cyclin
A are targets of both APC/CCdc20 and APC/CCdh1 (Geley
et al., 2001; McGarry and Kirschner, 1998). Because
APC/CCdc20 is activated prior to APC/CCdh1, this would
generate a window of time in telophase when geminin
and cyclin A have already been degraded but Cdc6 is
stable. Endoreduplication in giant trophoblast cells was
greatly reduced, and the generation of another poly-
ploid cell type, megakaryocytes, was compromised in
the cyclin E1−/−,E2−/− mice. Endoreduplication in cdc2
shut-off cells involves the periodic activation of APC/
CCdh1 but not APC/CCdc20 (Itzhaki et al., 1997; Laronne
et al., 2003). Thus, cells coming out of quiescence as
well as endoreduplicating cells may both need to li-
cense origins in the absence of APC/CCdc20, and cyclin
E-cdk2 may be required for this. In this regard, it is in-
teresting that Cdc6 levels positively correlate with
cyclin E expression in endoreduplicating human mega-
karyoblast cell lines (Bermejo et al., 2002).
Cdt1 is targeted for proteolysis after DNA damage,
thus restraining pre-RC assembly (Higa et al., 2003;
Kondo et al., 2004). Because CDKs are regulated in re-
Cell
924dependent synthesis of the CDK inhibitor, p21, DNA
damage may also destabilize Cdc6 protein, potentially
providing an additional mechanism for preventing li-
censing after DNA damage, perhaps contributing to the
p53-dependent checkpoint pathway involved in pre-
venting extensive rereplication when Cdt1 and Cdc6
are overexpressed (Vaziri et al., 2003).
Pre-RCs assemble in telophase, before the cell is
committed to replicate its DNA (Diffley et al., 1994;
Mendez and Stillman, 2000; Okuno et al., 2001). In bud-
ding yeast, pre-RCs assembled in mitosis disappear if
cells exit the cell cycle due to nutrient depletion (Diffley
et al., 1994). Quiescent mammalian cells also lack pre-
RCs, which has formed the basis of a diagnostic test
for neoplastic cells (Williams et al., 1998). Cdt1 and
Mcm2-7 disappear more slowly from quiescent cells
(data not shown). We suggest that, because of its ra-
pidity, the APC/C-dependent proteolysis of Cdc6 is the
primary mechanism for preventing licensing in quies-
cent cells. It will be of interest to know whether this
mechanism contributes to either genome stability or to
maintaining cells in a quiescent state. The availability
of the phospho-mimicking DDD mutant should allow
this to be tested in animal models.
Cyclin E can also play a negative role in licensing:
overproduction of cyclin E inhibits pre-RC assembly in
mammalian cells (Ekholm-Reed et al., 2004), analogous
to the effect of overproducing G1 cyclins in budding
yeast (Tanaka and Diffley, 2002). We suggest that cyclin
E exerts its negative effect on licensing through a factor
that is not present during the G0-G1 transition perhaps
because it, too, is an APC/C substrate. An attractive
candidate for such a factor is Skp2, a specificity factor
for the SCF ubiquitin ligase that targets CDK-phosphor-
ylated proteins (Ang and Harper, 2005) and is itself an
APC/CCdh1 target (Bashir et al., 2004; Wei et al., 2004).
Because the pathway leading to cyclin E activation is
misregulated in most cancer cells and cancers exhibit-
ing elevated cyclin E levels generally have a poor prog-
nosis, it will be important to determine whether the pos-
itive and/or negative roles cyclin E plays in pre-RC
assembly contribute to oncogenesis.
Experimental Procedures
Cell Culture and Drugs
Human U2OS osteosarcoma and T98G glioblastoma cells were
grown in DMEM containing 10% fetal bovine serum. The U2OS
T-REx cell line expressing the Tetracycline repressor (TetR) protein
was purchased from Invitrogen and maintained in DMEM as above
containing 100 g/ml Hygromycin B (Invitrogen). Stable cell lines
expressing siRNA-resistant HA-Cdc6 constructs in a Tetracycline-
responsive manner were isolated by transfecting U2OS T-REx cells
with pcDNA4/TO-HA-Cdc6 and selecting productively transfected
cells with 200 g/ml Zeocin (Invitrogen). A T98G-derivative cell line
(T98G-T) stably expressing the TetR protein was generated by se-
lecting cells transfected with pcDNA6/TR in medium containing 100
g/ml Zeocin. T98G cells were rendered quiescent by removing
serum from confluent cells for 72 hr, after which cells were stim-
ulated to reenter the cell cycle by trypsinization and replating at a
1:3 dilution in fresh medium containing 10% serum. To synchronize
cells in metaphase, 50 ng/ml Nocodazole (Sigma) was added to the
medium for 12 hr. Subsequently, cells were released from the block
by washing twice in PBS and replating in fresh medium. The follow-
ing drugs were used: 10 M MG132 (Sigma), 10 g/ml Roscovitine
(BioMol), 25 g/ml Cycloheximide (Sigma), and 1 g/ml Doxycy-
cline (Sigma).
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elasmids
pCGN.CSH.FL42 plasmid (Mendez and Stillman, 2000) encoding
-terminally HA-tagged full-length human Cdc6 was a gift from Dr.
. Stillman. For comparison of full length Cdc6 and Cdc6NT
amino acids 110–560), these sequences were amplified by PCR
nd cloned into pcDNA3.1 (Invitrogen) harboring an N-terminal HA
ag. Cyclin E and A cDNAs were subcloned into pcDNA3.1 contain-
ng an N-terminal myc tag. Plasmids expressing myc-Cdh1 (Lukas
t al., 1999) and pCMV-CD20 were gifts from Dr. J. Lukas. For Dox-
cycline-inducible (Tet-On) expression of Cdc6 and Cdh1, HA-Cdc6
ariants and myc-Cdh1 were amplified by PCR and inserted into
cDNA4/TO (Invitrogen). The Cdc6 AAA (S54A, S74A, S106A) and
DD (S54D, S74D, S106D) mutants were generated using the
uikChange Site-Directed Mutagenesis Kit (Stratagene). An ex-
ression plasmid for HA-tagged Cdt1 was a gift from Dr. K. Helin.
he pcDNA6/TR plasmid was obtained from Invitrogen. pBOS-
2B-GFP was from BD Pharmingen. Transfections were performed
sing FuGene6 (Roche) or Lipofectamine 2000 (Invitrogen) for
2OS and T98G cells, respectively, according to the manufacturers
nstructions. Unless otherwise stated, transfections were per-
ormed for a total of 24 hr.
ntibodies
ntibodies used in this study included mouse monoclonals to Cdc6
sc-9964), cyclin E (sc-247 and sc-248), Mcm7 (sc-9966), Cdc27
sc-9972), GFP (sc-9996), rabbit polyclonals to Cdc6 pSer54 (sc-
2920-R), cyclin A (sc-751), Geminin (sc-13015), HA-probe (sc-805),
nd goat polyclonals to Mcm6 (sc-9843) and Cdc20 (sc-1906), all
rom Santa Cruz Biotechnology. Rabbit ORC2 antibody (559266)
as from BD Pharmingen. Monoclonal Cdh1 antibody was a gift
rom Dr. T. Hunt, Cdt1 monoclonal antibody was a gift from Dr. K.
elin, and rabbit polyclonal Cdh1 and monoclonal cdk7 antibodies
ere gifts from Dr. J. Lukas. Other antibodies used were myc (9E10)
nd HA (12CA5).
iRNA
iRNA oligonucleotides (Dharmacon) were synthesized to the fol-
owing sequences (sense strand): Cdc6 (5#-AACUUCCCACCUUA
ACCAGA-3#), Cdh1 (5#-AAUGAGAAGUCUCCCAGUCAG-3#), cdk2
5#-AAGCCAGAAACAAGUUGACGG-3#), cyclin E1/E2 (5#-AACCAA
CUUGAGGAAAUCUA-3#), and GL2 (control) (5#-AACGUACGCGG
AUACUUCGA-3#). Transfections were performed with 100 nM
iRNA duplexes using Oligofectamine or Lipofectamine 2000 (both
rom Invitrogen) for U2OS or T98G cells, respectively, according to
he manufacturer’s instructions. To generate siRNA-resistant Cdc6
xpression constructs, two silent mutations (underlined) were intro-
uced into the Cdc6 siRNA target sequence (AATTTCCCGCCTTA
ACCAGA) by site-directed mutagenesis.
otal Cell Extracts and Chromatin Fractionation
o prepare total cell extracts, cells were lysed in EBC buffer (50 mM
ris [pH 7.5], 120 mM NaCl, 0.5% NP-40, 1 mM EDTA) containing 1
M DTT, 5 g/ml Leupeptin, 2 g/ml Aprotinin, 0.1 mM PMSF, 10
M β-Glycerophosphate, 1 mM NaF, and 0.1 mM Na3VO4, incu-
ated for 20 min on ice, sonicated briefly, and lysates were cleared
y centrifugation for 10 min at 20,000 rpm. For dephosphorylation
f total cell extracts, lysates were prepared using EBC buffer with-
ut phosphatase inhibitors and incubated with λ phosphatase
New England BioLabs) for 15 min at 37°C. To obtain chromatin-
nriched fractions, cells were separated into Triton X-100-soluble
nd -insoluble fractions essentially as described (Ballabeni et al.,
004). Briefly, cells were lysed in cytoskeleton (CSK) buffer (10 mM
IPES [pH 6.8], 100 mM NaCl, 1.5 mM MgCl2, 300 mM sucrose),
ontaining 0.5% Triton X-100, 1 mM ATP, 1mM DTT, 5 g/ml Leu-
eptin, 2 g/ml Aprotinin, and 0.1 mM PMSF for 20 min on ice.
ysed cells were then centrifuged for 4 min at 3200 rpm to obtain
he soluble fraction. The pellet was washed once with CSK buffer
or 5 min on ice, centrifuged for 4 min at 3200 rpm, and resus-
ended in 2× Laemmli Sample Buffer, then boiled for 3 min and
onicated for 10 s.
mmunoblotting, Immunoprecipitation, and Kinase Assays
mmunoblotting and immunoprecipitations were done as described
arlier (Mailand et al., 2000). For immunodepletion of Ser54-phos-
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925phorylated Cdc6, total cell extracts were subjected to three suc-
cessive rounds of immunoprecipitation with phospho-Ser54 anti-
body or preimmune rabbit serum for 1 hr at 4°C on an end-over-
end rotator. Measurements of cyclin E- and A-associated Histone
H1 kinase activities were done exactly as described (Mailand et
al., 2000).
Immunofluorescence
Cells grown on glass coverslips were fixed in ice-cold 1:1 (v/v)
Methanol:Acetone, and immunostained with antibodies specified in
figure legends and secondary Alexa Fluor 594 reagents (Molecular
Probes). To detect chromatin bound Mcm6, cells were washed with
CSK buffer once, extracted with CSK buffer containing 0.5% Triton
X-100, 1mM DTT, 5 g/ml Leupeptin, 2 g/ml Aprotinin, and 0.1
mM PMSF for 5 min at room temperature and washed again in CSK
buffer before fixation. Cells were visualized using a Zeiss 510 laser-
scanning microscope mounted on Axioplan 2 (Zeiss).
Ubiquitination and Degradation Assays
For detection of in vivo ubiquitin-conjugates of ectopic Cdc6, cells
were cotransfected with 6× His-tagged Ubiquitin (Treier et al.,
1994), and 6× His-tagged proteins were purified on Ni2+-NTA spin
columns (Qiagen) under denaturing conditions according to the
manufacturer’s instructions. The ability of immunopurified APCCdh1
to ubiquitinylate Cdc6 was assessed essentially as described
(Kramer et al., 2000); briefly, APC was immunoprecipitated with
Cdc27 antibodies from 3 mg of quiescent T98G cell extract,
washed extensively, preincubated with in vitro-translated Cdh1 for
30 min at 37°C, washed again, and incubated with 125 M Biotin-
conjugated unphosphorylated or Ser54/74-phosphorylated Cdc6
peptides (amino acids 49–88) in the presence of 1.25 mg/ml Ubiq-
uitin (Sigma), 5 M human E1 (Boston Biochem), 2 M hUbcH10
(Boston Biochem), and an energy-regenerating system for 20 min
at 37°C. Ubiquitinated peptides were detected by immunoblotting
with anti-Biotin antibody (Vector Laboratories). In vitro degradation
assays were performed as described (Rape and Kirschner, 2004),
using extracts from quiescent T98G cells and 35S-labeled N-ter-
minal fragments (amino acids 1–121) of Cdc6. Aliquots were re-
solved by 15% SDS-PAGE and autoradiography.
Purification of CD20-Positive Cells
Transfected cells expressing the CD20 surface marker were iso-
lated with Dynabeads (Dynal Biotech) according to the manufactur-
ers instructions. Briefly, cells transfected at a 1:10 ratio with pCMV-
CD20 were collected in PBS containing 0.1% EDTA, centrifuged
and resuspended in PBS containing 0.1% BSA, and incubated with
25 l Pan Mouse IgG Dynabeads coated with monoclonal CD20
antibody for 60 min at 4°C on an end-over-end rotator. Bound cells
were washed three times using a magnetic rack and processed for
total cell extract preparation or chromatin fractionation.
Supplemental Data
Supplemental Data include five figures and can be found with this
article online at http://www.cell.com/cgi/content/full/122/6/915/
DC1/.
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